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Purpose: Typically in Korea, for a standard dose (0.4 mg) of tamsulosin, two low doses 
(0.2 mg) are administered. The aim of this study was to evaluate and compare the effi-
cacy of tamsulosin (0.2 mg and 0.4 mg) and alfuzosin (10 mg) in the treatment of lower 
ureteral stones. 
Materials and Methods: A total of 141 patients presenting with a single 4- to 10-mm 
sized lower ureteral stone were randomly assigned to 4 groups. Patients in group 1 
(n=41) and group 2 (n=30) received an oral dose of 0.2 mg tamsulosin once and twice 
daily, respectively, and patients in group 3 (n=36) received a daily oral dose of 10 mg 
alfuzosin. Patients in group 4 (n=34) received trospium chloride only. The spontaneous 
passage of stones, the stone expulsion time, and adverse effects were evaluated. 
Results: There were no significant differences in patient background, including age, 
sex, BMI, stone size, stone side, and symptom duration. The spontaneous stone passage 
rate through the ureter was higher and the stone expulsion time was faster in groups 
1, 2, and 3 than in group 4. There were no statistically different changes in groups 1, 
2, and 3. The adverse effects observed in all groups were comparable and were mild. 
Conclusions: Tamsulosin at 0.2 mg and 0.4 mg and alfuzosin (10 mg) proved to be safe 
and effective. A first cycle of medical expulsive therapy with tamsulosin 0.2 mg could 
be considered as an option in the management of single lower ureteral stone.
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INTRODUCTION 
Patients with urinary tract stones account for 20% of urol-
ogy inpatients [1]. Urinary tract stones remain common, 
affecting up to 5% of people worldwide [2]. The prevalence 
of urinary tract stone disease in Korea is steadily rising. 
The location (upper, mid, and lower) and size of the stone 
as well as stone composition and complications are de-
termining factors in the treatment of urinary stones. 
Treatments are divided into three broad groups: 1) ob-
servation and medical therapy, 2) shock wave lithotripsy 
(SWL) and ureteroscopy, and 3) open surgery, laparoscopic 
stone removal, or percutaneous antegrade ureteroscopy. 
Urolithiasis treatment has been shifting to less invasive 
therapies such as SWL or ureteroscopy. Despite improved 
treatment, however, the rate of recurrence of urinary tract 
stones remains high. Tomson [3] reported a 67% and 75% 
recurrence of urolithiasis within 9 years and 25 years, 
respectively. Fifty percent of those with urinary tract 
stones will experience one or more recurrences. Therefore, 
the initial treatment is very important; no remaining 
stones should be present and ureteral injury, sepsis, and 
infection should not occur as a result of the intervention. 
For stones 5 to 10 mm in size, analysis of groups yielded 
an estimate that 47% would pass spontaneously [4]. 
Various studies of efficient stone expulsion have been done 
for increasing the stone expulsion rate. The 2007 Guideline 
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Urological Association (AUA) and the European Associa-
tion of Urology (EAU) guideline recommend watchful wait-
ing with medical treatment for patients with a stone ＜10 
mm in diameter and well-controlled pain [4]. 
Currently, non-selective α-blockers such as alfuzosin (10 
mg daily) and doxazosin (4 mg daily) and α-1a and α-1d se-
lective α-blockers such as tamsulosin (0.4 mg daily) are 
used for the spontaneous expulsion of lower ureteral stones 
or to facilitate stone removal after SWL [5-7]. In Korea and 
Japan, only tamsulosin 0.2 mg is produced and the admin-
istration of the total daily dose of tamsulosin is achieved 
by the use of two doses of 0.2 mg. This regimen is more oner-
ous and expensive than the use of a single 0.2-mg daily dose 
and adverse effects such as retrograde ejaculation can be 
increased. Adverse effects such as dizziness, orthostatic 
hypotension, headache, and fatigue may occur by taking 
nonselective α-blockers. 
Presently, we compared the impact of 0.2 mg tamsulosin 
with that of 0.4 mg tamsulosin and 10 mg alfuzosin in pa-
tients with lower ureteral stones of 4 to 10 mm in diameter 
and with controlled pain, with the aim of clarifying the 
treatment regimen that is superior for spontaneous stone 
expulsion. 
MATERIALS AND METHODS 
1. Materials
Patients presenting with only one single lower ureteral 
stone, 4 to 10 mm in size, at the emergency department or 
urologic clinic at our institution were evaluated for study 
participation in a prospective manner between September 
2008 and June 2011. Patients were enrolled upon diagnosis 
with normal renal function that did not require hospital-
ization and intervention for stone removal. The patients 
were excluded if they met any of following criteria: 1) uri-
nary tract infection, 2) moderate or severe hydronephrosis, 
3) hypotension, 4) single kidney, 5) bilateral ureteral 
stones, 6) history of previous surgery on the ipsilateral ure-
ter, 7) currently taking an α-blocker, steroid, or calcium 
channel blocker, 8) renal insufficiency, 9) ＜18 years of age, 
and 10) pregnant or lactating woman. A total of 156 pa-
tients were enrolled and 15 patients were excluded. The 
randomization list was generated by using the permuted 
block method and was concealed from the patient-enrolling 
investigators (confined with a doctor assisting in the proce-
dure but not participating in the study). When a patient 
met the inclusion and exclusion criteria, the assigned 
treatment was disclosed.
A total of 141 patients were classified into four treatment 
groups. All patients received an initial treatment of 90 mg 
diclofenac by intramuscular injection and 5 mg cime-
tropium bromide by intravenous injection, with a second 
dose after 30 minutes or 1 hour if necessary. All patients 
received trospium chloride (50 mg, tablet) every 8 hours un-
til their next visit. Patients in group 1 (n=41) and group 2 
(n=30) received an oral dose of 0.2 mg tamsulosin once or 
twice daily, respectively. Patients in group 3 (n=36) re-
ceived a daily oral dose of 10 mg alfuzosin. Patients in group 
4 (n=34) received trospium chloride. 
2. Methods
Before the treatment, urinalysis, blood urea nitrogen, crea-
tinine level, plain kidney ureter and bladder radiographs 
(KUB), intravenous pyelogram (IVP), or ultrasound views 
of the kidney, ureter, and bladder were obtained for all 
patients. If the stone was not identified exactly, un-
enhanced computed tomography (CT) was obtained. 
Similar measurements for stones 5 to 10 mm and 2 to 13 
mm in size have been reported between non-contrast spiral 
CT and plain KUB for distal ureteral stones [8,9]. 
Therefore, we evaluated stone location and size by using 
KUB images and noncontrast CT.
Follow-up visits were performed on days 7, 14, 21, and 
28. At each follow-up visit, the spontaneous passage of 
stones, the stone expulsion time, and side effects were eval-
uated and every patient underwent a plain KUB, ultra-
sonography, urinalysis, and determination of serum 
creatinine. Also, patients were asked to observe for stone 
passage during urination; if they had not noticed stone ex-
pulsion with a stone-free ureter, the mean date between the 
date of the last positive image study and the most recent 
follow-up was recorded. 
The study medications were discontinued after sponta-
neous stone expulsion, intervention, or at the end of the 
study period. No expulsion of the stone at the end of the 
study and intervention before the end of the study as the 
result of uncontrolled pain or other serious events were con-
sidered failed therapy. 
3. Statistical analyses
Statistical analysis was performed by using SPSS ver. 13.0 
(SPSS Inc., Chicago, IL, USA) software. One-way analysis 
of variance was used to compare continuous variables be-
tween the four groups, and different continuous variables 
between the two groups were tested by using Student's 
t-test. Nominal parameters were analyzed by using 
Pearson's chi-square and Fischer's exact test. A p-value
＜0.05 was considered significant. 
RESULTS 
1. Patient characteristics
The mean stone size was 5.49±1.31 mm for group 1, 
5.73±1.57 mm for group 2, 5.81±1.26 mm for group 3, and 
5.59±1.44 mm for group 4. There were no statistically sig-
nificant differences between the four groups with respect 
to age, sex, body mass index, stone size, stone localization, 
or symptom duration. The demographic data are summar-
ized in Table 1.
2. Stone expulsion rate
The calculi passed through the ureter spontaneously in 32 
patients in group 1 (78.0%), 23 patients in group 2 (76.7%), 
27 patients in group 3 (75.0%), and 16 patients in group 4 Korean J Urol 2012;53:349-354
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TABLE 1. Baseline patient characteristics
Characteristic Group 1 (n=41) Group 2 (n=30)  Group 3 (n=36) Group 4 (n=34) p-value
Mean age (yr)
Sex (male:female) 
Body mass index (kg/m
2)
Stone size (mm) 
Stone side (right/left) 
Symptom duration (day)
45.07±13.77
31:10
24.18±0.88
5.49±1.31
18/23
3.15±1.56
45.50±11.09
20:10
24.34±1.00 
5.73±1.57
12/18
3.07±1.55
42.33±12.58
25:11
24.10±0.97 
5.81±1.26
19/17
2.53±1.18
43.65±10.87
18:16
24.42±0.93
5.59±1.44
14/20
2.82±1.14
0.696
a
0.287
b
0.476
a
0.757
a
0.588
b
0.217
a
Values are presented as mean±SD.
Group 1, tamsulosin 0.2 mg once; Group 2, tamsulosin 0.2 mg twice; Group 3, alfuzosin 10 mg; Group 4, control group.
a: Statistical significance was analyzed by one-way analysis of variance, 
b: Statistical significance was analyzed by chi-square test.
TABLE 2. Results according to treatment
Group 1 (n=41) Group 2 (n=30)  Group 3 (n=36) Group 4 (n=34)
Stone expulsion rate at 28 days
Mean days to stone expulsion 
32 (78.0)
8.47±5.51
23 (76.7)
7.83±5.08
27 (75.0)
8.22±5.96
16 (47.1)
13.56±6.49
Values are presented as number (%) or mean±SD.
Group 1, tamsulosin 0.2 mg once; Group 2, tamsulosin 0.2 mg twice; Group 3, alfuzosin 10 mg; Group 4, control group.
TABLE 3. Adverse effects observed in patients
Symptom/sign Group 1 (n=41) Group 2 (n=30)  Group 3 (n=36) Group 4 (n=34)
Retrograde ejaculation 
Orthostatic hypotension
Headache
Dizziness
Diarrhea 
Fatigue 
Nausea/vomiting
2 (4.9)
1 (2.4)
2 (4.9)
2 (4.9)
2 (4.9)
2 (4.9)
4 (9.8)
2 (6.7)
1 (3.3)
2 (6.7)
  3 (10.0)
2 (6.7)
2 (6.7)
  3 (10.0)
0 (0)
2 (5.6)
2 (5.6)
3 (8.3)
2 (5.6)
  4 (11.1)
3 (8.3)
0 (0)
0 (0)
2 (5.9)
2 (5.9)
  4 (11.8)
2 (5.9)
  4 (11.8)
Values are presented as number (%).
Group 1, tamsulosin 0.2 mg once; Group 2, tamsulosin 0.2 mg twice; Group 3, alfuzosin 10 mg; Group 4, control group. 
Statistical significance was analyzed by the Pearson's chi-square and Fischer's exact test. There were no statistically significant differ-
ences in any groups. 
(47.1%). A statistically significant difference was noted be-
tween groups 1 and 4 (p=0.008), groups 2 and 4 (p=0.021), 
and groups 3 and 4 (p=0.026), whereas no significant differ-
ence was recorded between groups 1 and 2 (p=1.000), 
groups 1 and 3 (p=0.793), and groups 2 and 3 (p=1.000). The 
demographic data are summarized in Table 2.
3. Stone expulsion time
The mean time to stone expulsion was 8.47±5.51 days in 
group 1, 7.82±5.08 days in group 2, 8.22±5.96 days in group 
3, and 13.56±6.49 days in group 4. A statistically sig-
nificant difference was noted between groups 1 and 4 
(p=0.007), groups 2 and 4 (p=0.004), and groups 3 and 4 
(p=0.009), whereas no significant difference was recorded 
between groups 1 and 2 (p=0.661), groups 1 and 3 (p=0.870), 
and groups 2 and 3 (p=0.803). The demographic data are 
summarized in Table 2. 
4. Side effects observed in the study and control groups
No severe complications were recorded in the four groups. 
Two patients (4.9%) in group 1 and two patients (6.7%) in 
group 2 recorded retrograde ejaculation. One patient (2.4 
%) in group 1, one patient (3.3 %) in group 2, and two pa-
tients (5.6 %) in group 3 recorded one episode of orthostatic 
hypotension that did not require suspension of the therapy. 
There were no statistically significant differences between 
the groups in terms of retrograde ejaculation, orthostatic 
hypotension, headache, dizziness, diarrhea, fatigue, nau-
sea, or vomiting (p＞0.05). The demographic data are sum-
marized in Table 3. During the course of the study, none 
of the patients experienced intractable pain, fever, or se-
vere hydronephrosis that required urgent intervention. A 
total of 43 patients who did not pass the stone within 4 
weeks were treated by using SWL or ureteroscopy. Korean J Urol 2012;53:349-354
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DISCUSSION 
Various treatment options are considered for the manage-
ment of lower ureteral stones, including open ureter-
olithotomy, ureteroscopic lithotripsy (URS), and SWL. 
According to the 2007 Guideline for the Management of 
Ureteral Calculi of the AUA and the EAU guideline, URS 
stone-free rates were significantly better than SWL rates 
for distal ureteral stones ≤10 mm and ＞10 mm [4]. The 
availability of this modality and physician experience were 
considered. Complications such as sepsis, stricture, ure-
teral injury, and urinary tract infection are the most rele-
vant complications. 
Spontaneous stone passage was often reported without 
active treatment including URS and SWL. One study re-
ported spontaneous expulsion in 25 to 53% of cases for dis-
tal ureteral stones 5 to 10 mm in diameter [10]. Another 
study reported spontaneous passage of 68% of stones ＜5 
mm in diameter and 47% of stones 5 to 10 mm in diameter 
[5]. Ureteric calculi more than 10 mm in diameter should 
be removed by emergency URS or medical expulsion treat-
ment (MET), because large calculi tend to impact in the ure-
ter and are unlikely to migrate in the distal region [11]. 
More distal stones are more likely to pass spontaneously, 
and Miller and Kane [12] reported that the interval to stone 
passage was highly variable and dependent on stone size 
and location. The hazard of expulsion at any time was 3-fold 
higher for stones located at the ureterovesical junction 
than for those in the distal part of the ureter [13]. 
Accordingly, the most important factors in predicting the 
likelihood of spontaneous stone expulsion are stone size 
and stone location [14]. 
The ureter demonstrates two continuous thin muscle 
layers with a loosely spiraled internal layer and a more 
tightly spiraled external layer. In the lower third of the ure-
ter, a third outer longitudinal layer is present. The lower 
ureter is composed of transitional epithelium, a connective 
tissue layer, and three layers of smooth muscle [15]. 
Ureteral peristalsis is initiated by spontaneous activity of 
the renal pelvis pacemaker cell and is essentially regulated 
by the myogenic mechanism and neurogenic factors; there-
after, electrical and mechanical activities are conducted to 
inactive distal regions [16]. The α-adrenoceptor pathway 
was first described in the human ureter in the 1970s [17]. 
Activation of α1-adrenoceptors leads to ureteral con-
traction via activation of phospholipase C, which in turn 
leads to the formation of second messengers (inositol tri-
phosphanate [IP3] and diacylglycerol [DAG]). IP3 is in-
volved in the mobilization of calcium from the sarcoplasmic 
reticulum, whereas DAG increases calcium influx across 
the cell membrane via the activation of protein kinase C 
[18]. Thus, the histologic characteristics of the three 
smooth muscle layers in the lower ureter and the more 
dense innervation of the lower ureter than the upper and 
mid ureter have become subjects of research interest.
The stimulation of the α1-receptors in the incomplete or 
complete ureteral obstruction by ureteral calculi increases 
the force of ureteral contraction and the frequency of ure-
teral peristalsis. Thus, a blockade of α1-receptors inhibits 
basal tone, reduces peristaltic amplitude and frequency, 
and decreases intra-luminal pressure. α-blockers also in-
duce an increase in the intra-ureteral pressure gradient 
around the stones that helps in stone expulsion [19]. 
Patients who elect for an attempt at MET, such as the use 
of an α-blocker, should have well-controlled pain, no clin-
ical evidence of sepsis, and adequate renal functional 
reserve. The patients should be followed with periodic 
imaging studies to monitor stone position and to assess for 
hydronephrosis or severe adverse effects. If the outcome of 
this treatment is not satisfactory, active stone removal mo-
dalities like URS or SWL should be required [4]. Follow-up 
at 7, 14, 21, and 28 days with blood test, urine test, and ra-
diologic test should be practiced for such serious 
conditions. It is very important that the patient be advised 
of the attendant risk including the associated side effects 
of treatment modalities like URS, SWL, and MET, and that 
MET should be performed. 
Medical treatments using nonselective α-blockers for 
spontaneous stone expulsion have been reported. Agrawal 
et al. [20] reported that for stones ≤  1 cm, 10 mg alfuzosin 
results in a 35% increase in the stone expulsion rate, de-
creased expulsion time, and good control of colic pain com-
pared with a control group. Pedro et al. [5] reported good 
pain control and stone expulsion time compared with a con-
trol group by using alfuzosin but found no significant differ-
ence in the stone expulsion rate between the afluzosin and 
control groups (73.5% vs. 77.1%). In the latter study, it is 
possible that the high rate of stone expulsion in the control 
group was unrelated to the effect of alfuzosin but rather re-
flected the small size of the stones in both groups (4.08 mm 
and 3.83 mm). In our study, the alfuzosin group displayed 
a 27.9% increased stone expulsion rate compared with the 
control group (p=0.026). 
The α-1d receptor has the highest density in the distal 
ureter [18]. Tamsulosin, which is a selective α-1a and α-1d 
blocker, is a commonly used α-blocker for the medical treat-
ment of ureteric stones. Al-Ansari et al. [21] reported that 
0.4 mg tamsulosin produced a 26% increased stone ex-
pulsion rate and decreased stone expulsion time. Resim et 
al. [7] reported that the same dose of tamsulosin produced 
an insignificantly increased rate of stone expulsion (13.3%) 
and decreased colic episodes and pain. Hermanns et al. [13] 
reported no significant difference in the expulsion rate be-
tween the group using 0.4 mg tamsulosin and the control 
group (86.7% vs. 88.9%, respectively). However, these re-
sults involved small-sized stones (mean, 3.8 mm) in both 
groups, similar to the study of Pedro et al. [5]. 
In Korea and Japan, 0.2 mg tamsulosin is taken orally 
twice daily to achieve the affects attributed to 0.4 mg 
tamsulosin. This regimen is expensive and onerous and ad-
verse effects such as retrograde ejaculation and fatigue can 
be increased. In our country, 0.2 mg tamsulosin is used for 
control of symptoms of benign prostatic hyperplasia; be-
cause the α-1d receptor is more dense in the lower ureter, Korean J Urol 2012;53:349-354
Comparison and Efficacy of Alpha Blockers in MET 353
we used the same dose of tamsulosin for MET. Yoon et al. 
[22] reported that the use of 0.2 mg tamsulosin produced 
a 25.7% increased stone expulsion rate and decreased ex-
pulsion time for 3 days for stones ＜10 mm in diameter. In 
two other studies, 0.2 mg tamsulosin resulted in increased 
stone migration and an increased stone expulsion rate 
[23,24]. However, studies that have compared tamsulosin 
0.2 mg and 0.4 mg are not much more prevalent than those 
that have compared a nonselective α-blocker and 
tamsulosin. In particular, to our knowledge, the present 
study is the first direct comparison of 10 mg alfuzosin, 0.2 
mg tamsulosin, and 0.4 mg tamsulosin in the management 
of lower ureteral calculi. 
Comparison between the two tamsulosin doses and the 
10-mg alfuzosin dose revealed no significant differences in 
expulsion rate or expulsion time. The expulsion time ob-
served in this study was shorter than reported previously 
[25]. The higher expulsion rate observed with 0.2 mg tam-
sulosin compared with 0.4 mg tamsulosin was likely not a 
statistical error caused by the small numbers of subjects, 
but rather that the lower dose of tamsulosin was sufficient 
to lower ureteral peristalsis. 
Similar to a previous study [26], all groups treated in this 
study with 0.2 mg tamsulosin, 0.4 mg tamsulosin, and 10 
mg alfuzosin displayed no differences in postural 
hypotension. There were also no differences in dizziness, 
headache, and fatigue in these groups, which is also con-
sistent with other studies [7,18,20]. Although tamsulosin 
has been linked to a higher incidence of retrograde ejacu-
lation than the non-selective α-blocker alfuzosin [20], in 
our study, there was no significant difference in abnormal 
ejaculation between the groups. Whether the current re-
sult is real is debatable. The short-term nature of this study 
and the less frequent sexual behavior of urinary stone pa-
tients may have confounded the findings. 
When a single ureteral stone remains after 28 days of 
medical treatment, URS, SWL, and a second cycle of MET 
can be used for stone removal. A second cycle of tamsulosin 
therapy in nonresponders to a first cycle of MET may not 
significantly improve the expulsion rate [27]. Hubner et al. 
[28] reported that a maximum observation period of 30 
days was chosen because a longer period could increase the 
complication rate by 20%. Thus, we advocate the need for 
aggressive stone removal such as URS or SWL when the 
first cycle of MET has failed.
CONCLUSIONS 
The use of tamsulosin doses of 0.2 mg and 0.4 mg and of 10 
mg alfuzosin for MET of single lower ureteral stones of 4 
to 10 mm in diameter proved to be safe and effective as dem-
onstrated by the increased stone expulsion rate, decreased 
expulsion time, and no significantly different adverse 
effects. We confirm that a first cycle of MET with 0.2 mg 
tamsulosin is safe and effective and can be considered as 
an option in the management of a single lower ureteral 
stone.
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